HUE053346T2 - 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése - Google Patents
2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszereléseInfo
- Publication number
- HUE053346T2 HUE053346T2 HUE15744702A HUE15744702A HUE053346T2 HU E053346 T2 HUE053346 T2 HU E053346T2 HU E15744702 A HUE15744702 A HU E15744702A HU E15744702 A HUE15744702 A HU E15744702A HU E053346 T2 HUE053346 T2 HU E053346T2
- Authority
- HU
- Hungary
- Prior art keywords
- triazin
- quinolin
- imidazo
- benzamide
- ylmethyl
- Prior art date
Links
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 title 1
- 239000007916 tablet composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028865P | 2014-07-25 | 2014-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE053346T2 true HUE053346T2 (hu) | 2021-06-28 |
Family
ID=53762251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15744702A HUE053346T2 (hu) | 2014-07-25 | 2015-07-22 | 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése |
| HUS2200054C HUS2200054I1 (hu) | 2014-07-25 | 2022-12-19 | 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUS2200054C HUS2200054I1 (hu) | 2014-07-25 | 2022-12-19 | 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US10085993B2 (enExample) |
| EP (2) | EP3848376A1 (enExample) |
| JP (3) | JP6770946B2 (enExample) |
| KR (2) | KR20230136693A (enExample) |
| CN (2) | CN115364061A (enExample) |
| AR (1) | AR101286A1 (enExample) |
| AU (4) | AU2015293539A1 (enExample) |
| CA (1) | CA2954840A1 (enExample) |
| CL (1) | CL2017000180A1 (enExample) |
| CO (1) | CO2017000586A2 (enExample) |
| DK (1) | DK3172209T3 (enExample) |
| EA (2) | EA039220B1 (enExample) |
| EC (1) | ECSP17011672A (enExample) |
| ES (1) | ES2857523T3 (enExample) |
| FR (1) | FR22C1058I2 (enExample) |
| GT (1) | GT201700007A (enExample) |
| HU (2) | HUE053346T2 (enExample) |
| IL (1) | IL250166B (enExample) |
| JO (1) | JO3618B1 (enExample) |
| MX (2) | MX379279B (enExample) |
| MY (1) | MY187276A (enExample) |
| NL (1) | NL301208I2 (enExample) |
| NO (1) | NO2022058I1 (enExample) |
| PE (1) | PE20170523A1 (enExample) |
| PH (1) | PH12017500121A1 (enExample) |
| PL (1) | PL3172209T3 (enExample) |
| PT (1) | PT3172209T (enExample) |
| SG (2) | SG11201700147SA (enExample) |
| SI (1) | SI3172209T1 (enExample) |
| TW (2) | TW202200148A (enExample) |
| WO (1) | WO2016012963A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2868202C (en) | 2012-04-03 | 2021-08-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
| DK3172209T3 (da) | 2014-07-25 | 2021-02-22 | Novartis Ag | Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid |
| TWI736660B (zh) | 2016-08-10 | 2021-08-21 | 瑞士商赫孚孟拉羅股份公司 | 包含Akt蛋白質激酶抑制劑之醫藥組合物 |
| US11407735B2 (en) | 2019-05-16 | 2022-08-09 | Novartis Ag | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
| JP7675071B2 (ja) * | 2019-10-24 | 2025-05-12 | ハンミ ファーマシューティカル カンパニー リミテッド | がん細胞の成長を阻害するアミド誘導体を含む医薬調製物およびそれを含有する医薬品 |
| WO2022007752A1 (zh) * | 2020-07-06 | 2022-01-13 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法 |
| CN114853762A (zh) * | 2021-02-03 | 2022-08-05 | 四川科伦药物研究院有限公司 | 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途 |
| CN118251220A (zh) * | 2022-01-19 | 2024-06-25 | 江苏奥赛康药业有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
| WO2023249994A1 (en) * | 2022-06-22 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| AU2023324893A1 (en) * | 2022-08-19 | 2025-03-13 | Mirati Therapeutics, Inc. | Adagrasib solid pharmaceutical compositions |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6762778B1 (en) | 1999-06-10 | 2004-07-13 | Dassault Systemes | Three dimensional graphical manipulator |
| CA2465565A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| EP1909777A2 (en) * | 2005-07-22 | 2008-04-16 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
| WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
| CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| PL2497470T3 (pl) | 2006-11-22 | 2016-04-29 | Incyte Holdings Corp | Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy |
| JP6022158B2 (ja) | 2008-05-21 | 2016-11-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法 |
| PT4066821T (pt) * | 2009-11-09 | 2025-06-03 | Wyeth Llc | Formulações de comprimidos de maleato de neratinib |
| JP5846647B2 (ja) | 2010-02-25 | 2016-01-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アピキサバン製剤 |
| NZ603686A (en) * | 2010-05-21 | 2014-11-28 | Incyte Corp | Topical formulation for a jak inhibitor |
| WO2012006298A2 (en) | 2010-07-06 | 2012-01-12 | Janssen Pharmaceutica Nv | Formulation for co-therapy treatment of diabetes |
| RU2705095C2 (ru) | 2012-08-16 | 2019-11-05 | Новартис Аг | Комбинация ингибитора pik3 и ингибитора с-мет |
| DK3172209T3 (da) | 2014-07-25 | 2021-02-22 | Novartis Ag | Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid |
-
2015
- 2015-07-22 DK DK15744702.0T patent/DK3172209T3/da active
- 2015-07-22 SI SI201531507T patent/SI3172209T1/sl unknown
- 2015-07-22 KR KR1020237031767A patent/KR20230136693A/ko not_active Ceased
- 2015-07-22 PL PL15744702T patent/PL3172209T3/pl unknown
- 2015-07-22 AU AU2015293539A patent/AU2015293539A1/en not_active Abandoned
- 2015-07-22 CN CN202210949714.1A patent/CN115364061A/zh active Pending
- 2015-07-22 EP EP20210458.4A patent/EP3848376A1/en not_active Withdrawn
- 2015-07-22 ES ES15744702T patent/ES2857523T3/es active Active
- 2015-07-22 PE PE2017000097A patent/PE20170523A1/es unknown
- 2015-07-22 CA CA2954840A patent/CA2954840A1/en active Pending
- 2015-07-22 SG SG11201700147SA patent/SG11201700147SA/en unknown
- 2015-07-22 EA EA201790259A patent/EA039220B1/ru unknown
- 2015-07-22 EA EA202191301A patent/EA202191301A1/ru unknown
- 2015-07-22 MX MX2017001177A patent/MX379279B/es unknown
- 2015-07-22 WO PCT/IB2015/055561 patent/WO2016012963A1/en not_active Ceased
- 2015-07-22 PT PT157447020T patent/PT3172209T/pt unknown
- 2015-07-22 MY MYPI2017700061A patent/MY187276A/en unknown
- 2015-07-22 CN CN201580052264.4A patent/CN106714784A/zh active Pending
- 2015-07-22 KR KR1020177004939A patent/KR102581121B1/ko active Active
- 2015-07-22 HU HUE15744702A patent/HUE053346T2/hu unknown
- 2015-07-22 EP EP15744702.0A patent/EP3172209B1/en active Active
- 2015-07-22 US US15/328,661 patent/US10085993B2/en active Active
- 2015-07-22 SG SG10201900648SA patent/SG10201900648SA/en unknown
- 2015-07-22 JP JP2017504062A patent/JP6770946B2/ja active Active
- 2015-07-23 AR ARP150102336A patent/AR101286A1/es unknown
- 2015-07-23 TW TW110109338A patent/TW202200148A/zh unknown
- 2015-07-23 TW TW104123937A patent/TWI724993B/zh active
- 2015-07-23 JO JOP/2015/0174A patent/JO3618B1/ar active
-
2017
- 2017-01-17 IL IL250166A patent/IL250166B/en active IP Right Grant
- 2017-01-20 PH PH12017500121A patent/PH12017500121A1/en unknown
- 2017-01-24 CO CONC2017/0000586A patent/CO2017000586A2/es unknown
- 2017-01-24 CL CL2017000180A patent/CL2017000180A1/es unknown
- 2017-01-25 GT GT201700007A patent/GT201700007A/es unknown
- 2017-01-25 MX MX2021000595A patent/MX2021000595A/es unknown
- 2017-02-24 EC ECIEPI201711672A patent/ECSP17011672A/es unknown
-
2018
- 2018-07-23 AU AU2018207947A patent/AU2018207947A1/en not_active Abandoned
- 2018-09-18 US US16/134,162 patent/US10596178B2/en active Active
-
2020
- 2020-02-07 AU AU2020200912A patent/AU2020200912B2/en active Active
- 2020-02-13 US US16/789,655 patent/US20210113569A1/en not_active Abandoned
- 2020-03-27 JP JP2020058164A patent/JP7002587B2/ja active Active
-
2021
- 2021-04-23 AU AU2021202500A patent/AU2021202500A1/en not_active Abandoned
- 2021-12-15 US US17/644,473 patent/US12208101B2/en active Active
- 2021-12-24 JP JP2021211526A patent/JP2022046659A/ja active Pending
-
2022
- 2022-12-06 FR FR22C1058C patent/FR22C1058I2/fr active Active
- 2022-12-16 NL NL301208C patent/NL301208I2/nl unknown
- 2022-12-16 NO NO2022058C patent/NO2022058I1/no unknown
- 2022-12-19 HU HUS2200054C patent/HUS2200054I1/hu unknown
-
2024
- 2024-12-16 US US18/982,128 patent/US20250339440A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200054I1 (hu) | 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése | |
| IL283258A (en) | Treatment of hypoparathyroidism | |
| IL264143B (en) | Processes for preparing olaparib | |
| HUE043122T2 (hu) | Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk | |
| PL3936130T3 (pl) | Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu | |
| EP3452481A4 (en) | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| EP3096111A4 (en) | Hemispherical resonator gyro | |
| IL254476A0 (en) | Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists | |
| IL254168A0 (en) | Use of 3,2-dihydroimidazo[2,1-c]converted quinazolines | |
| DK3296299T3 (da) | Krystalform af 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1h-pyrazol-4-yl)-1h- imidazol-1-yl)-1h-pyrazolo[3,4-b]pyridin-1-yl}benzamid | |
| HUE054245T2 (hu) | Immunszupresszáns formuláció | |
| GB201802644D0 (en) | Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | |
| HRP20180788T1 (hr) | [1,2,4]triazolo[4,3-b]piridazini za uporabu za liječenje proliferativnih bolesti | |
| LT3230289T (lt) | 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai | |
| SI3362453T1 (sl) | Derivati cikličnega etra pirazolo(1,5-A)pirimidin-3-karboksiamida | |
| IL263167A (en) | Pharmacy preparation | |
| PL3478684T3 (pl) | Nowe sposoby otrzymywania wemurafenibu | |
| PL3145490T3 (pl) | Liposomy zawierające kwas dihomo-gamma-linolenowy (dgla), zawierające je preparaty i ich zastosowanie | |
| TWM533077U (en) | Pharmaceutical solution manufacturing equipment | |
| TH1601003084A (th) | สิ่งจัดเตรียมใช้ภายนอกที่ผิวหนัง | |
| GB201515844D0 (en) | Location-based active filtering | |
| GB201604545D0 (en) | Novel pharmaceutical formulation | |
| TH1501005812A (th) | อนุพันธ์แนพธิริดีนที่ใช้ประโยชน์เป็นแอลฟา-v-บีตา-6 อินทีกรินแอนทาโกนิสต์ | |
| TH1601001753A (th) | อุปกรณ์สำหรับการเปลี่ยนแปลงรูปร่างการพ่นของผลิตภัณฑ์ที่ไหลได้อย่างอิสระ |